This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Jiancun Larry Zhang, Ph.D.
President and CEO at Guangzhou Henovcom Biosciences
Speaker

Profile

Dr. Zhang obtained his BS degree in chemistry from Fudan University and his Ph. D degree in organic chemistry in 1990 from the University of Pittsburgh. After postdoctoral training at Duke University, he joined Gilead in 1992 working on various antisense ODN and antiviral projects. He is the co-founder of Henovcom Biosciences. Over the years, he has co-invented several NMEs that are marketed or in clinical development. He co-authored over 80 publications and is the co-inventors of over 100 patents and patent applications in organic and medicinal chemistry.

Agenda Sessions

  • Enhancing mRNA Translation Efficiency through Trinucleotide Cap Modifications

    8:30am